Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients

QJM: An International Journal of Medicine

Volumn 104, Issue 3, 2011, Pages 221-230

  Sinha, S ^a   Chiu, D ^a   Peebles, G ^b   Swoboda, P ^c   Kolakkat, S ^a   Lamerton, E ^a   Fenwick, S ^b   Bhandari, S ^c   Kalra, P A ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST   (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; DEXTRAN DERIVATIVE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; HYDROCORTISONE; IRON; IRON DEXTRAN; LOW MOLECULAR WEIGHT IRON DEXTRAN; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; COLD CLAMMY SKIN; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOTENSION; KIDNEY TRANSPLANTATION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TOTAL DOSE INFUSION; TREATMENT OUTCOME; URTICARIA; WHEEZING;

EID: 79953802840     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq180     Document Type: Article

References (22)

1. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18:89-100.
2. Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999; 69:S18-21.
3. Bhandari S, Brownjohn AM, Turney JH. Response of mean reticulocyte haemoglobin content to intravenous iron therapy in haemodialysis patients. Nephrol Dial Transplant 1998; 13:3276-7.
4. Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694-9.
5. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 48:34-40.
6. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients. J Am Soc Nephrol 2000; 11:530-8.
7. National Collaborating Centre for Chronic Conditions. Anaemia management in chronic kidney disease. National Institute for Health and Clinical Excellence. [http://www.nice.org.uk/Guidance/CG39.27-9-2006]. (Accessed 7 October 2009).
8. Auerbach M, Al TK. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008; 73:528-30.
9. Bhandari S, Naudeer S. Improving efficiency and value in health care: Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J Eval Clin Pract 2008; 14:996-1001.
10. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378-82.
11. Critchley J, Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfus Altern Transfus Med 2007; 9:8-36.
12. Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med 2007; 9:39-42.
13. Levey AS, Greene T, Kusek JW, Beck GJ. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11:A0828.
14. Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008; 19:833-4.
15. Vaage-Nilsen O. Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer. Nephrol Dial Transplant 2008; 23:3372.
16. Sav T, Tokgoz B, Sipahioglu MH, Deveci M, Sari I, Oymak O, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29:423-6.
17. Sinha S, Chiu DY, Peebles G, Kolakkat S, Lamerton E, Fenwick S, et al. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease. J Ren Care 2009; 35:67-73.
18. Garneata L. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients? J Ren Nutr 2008; 18:40-5.
19. Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19:1817-26.
20. Auerbach M. Ferumoxytol as a new, safer, easier-toadminister intravenous iron: yes or no? Am J Kidney Dis 2008; 52:826-9.
21. Auerbach M, Winchester J, Wahab A, Richards K, McGinley M, Hall F. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31:81-6.
22. Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68:1801-7.